CARES Phase III clinical program for anselamimab misses primary goal

UK pharma major AstraZeneca (LSE: AZN) today disclosed that the global CARES Phase III clinical program showed that treatment with anselamimab, a potential first-in-class anti-fibril therapy, resulted in nominally statistically significant and highly clinically meaningful benefit in adults with advanced kappa light chain (AL) amyloidosis as first-line therapy added to standard of care plasma cell dyscrasia (PCD) treatments, compared to placebo.

However, in the overall population of patients with AL amyloidosis, treatment with anselamimab did not meet the primary endpoint, defined as a hierarchical combination of time to all-cause mortality (ACM) and frequency of cardiovascular hospitalizations (CVH).